NovoCure Limited (NVCR)
USD 15.37
(-7.47%)
USD 15.37
(-7.47%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 38.15 Million USD | 29.87% |
| 2022 | 29.37 Million USD | 20.26% |
| 2021 | 24.42 Million USD | -10.92% |
| 2020 | 27.42 Million USD | 15.7% |
| 2019 | 23.7 Million USD | 5.08% |
| 2018 | 22.55 Million USD | 2.41% |
| 2017 | 22.02 Million USD | -13.79% |
| 2016 | 25.54 Million USD | 87.94% |
| 2015 | 13.59 Million USD | 294.49% |
| 2014 | 3.44 Million USD | 82.14% |
| 2013 | 1.89 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 42.39 Million USD | 11.11% |
| 2024 Q2 | 40.44 Million USD | -4.6% |
| 2024 Q3 | 39.09 Million USD | -3.33% |
| 2023 Q4 | 38.15 Million USD | 3.66% |
| 2023 Q3 | 36.8 Million USD | 11.46% |
| 2023 Q2 | 33.02 Million USD | 4.1% |
| 2023 Q1 | 31.72 Million USD | 7.99% |
| 2023 FY | 38.15 Million USD | 29.87% |
| 2022 Q2 | 29.53 Million USD | 1.54% |
| 2022 FY | 29.37 Million USD | 20.26% |
| 2022 Q3 | 26.79 Million USD | -9.27% |
| 2022 Q4 | 29.37 Million USD | 9.64% |
| 2022 Q1 | 29.08 Million USD | 19.06% |
| 2021 Q2 | 26.69 Million USD | -4.57% |
| 2021 FY | 24.42 Million USD | -10.92% |
| 2021 Q3 | 22.64 Million USD | -15.17% |
| 2021 Q4 | 24.42 Million USD | 7.88% |
| 2021 Q1 | 27.96 Million USD | 1.99% |
| 2020 Q2 | 26.13 Million USD | 16.15% |
| 2020 FY | 27.42 Million USD | 15.7% |
| 2020 Q4 | 27.42 Million USD | 3.56% |
| 2020 Q3 | 26.47 Million USD | 1.31% |
| 2020 Q1 | 22.5 Million USD | -5.06% |
| 2019 Q4 | 23.7 Million USD | -2.82% |
| 2019 FY | 23.7 Million USD | 5.08% |
| 2019 Q3 | 24.38 Million USD | -4.19% |
| 2019 Q2 | 25.45 Million USD | 5.45% |
| 2019 Q1 | 24.13 Million USD | 7.02% |
| 2018 Q4 | 22.55 Million USD | 4.22% |
| 2018 FY | 22.55 Million USD | 2.41% |
| 2018 Q1 | 20.38 Million USD | -7.44% |
| 2018 Q2 | 19.9 Million USD | -2.35% |
| 2018 Q3 | 21.64 Million USD | 8.72% |
| 2017 Q4 | 22.02 Million USD | -10.62% |
| 2017 FY | 22.02 Million USD | -13.79% |
| 2017 Q1 | 25.94 Million USD | 1.57% |
| 2017 Q2 | 25.14 Million USD | -3.09% |
| 2017 Q3 | 24.64 Million USD | -2.01% |
| 2016 FY | 25.54 Million USD | 87.94% |
| 2016 Q4 | 25.54 Million USD | 6.58% |
| 2016 Q3 | 23.97 Million USD | 13.0% |
| 2016 Q2 | 21.21 Million USD | 29.0% |
| 2016 Q1 | 16.44 Million USD | 20.98% |
| 2015 Q2 | 8.59 Million USD | 19.71% |
| 2015 FY | 13.59 Million USD | 294.49% |
| 2015 Q1 | 7.17 Million USD | 108.3% |
| 2015 Q4 | 13.59 Million USD | 21.93% |
| 2015 Q3 | 11.14 Million USD | 29.75% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 3.44 Million USD | 82.14% |
| 2014 Q4 | 3.44 Million USD | 0.0% |
| 2013 FY | 1.89 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 17.87 Million USD | -113.414% |
| AngioDynamics, Inc. | 60.61 Million USD | 37.06% |
| AtriCure, Inc. | 67.89 Million USD | 43.809% |
| Avinger, Inc. | 5.29 Million USD | -620.121% |
| Azenta, Inc. | 128.19 Million USD | 70.24% |
| BioLife Solutions, Inc. | 43.45 Million USD | 12.205% |
| The Cooper Companies, Inc. | 735.6 Million USD | 94.813% |
| Daxor Corporation | - USD | -Infinity% |
| Ekso Bionics Holdings, Inc. | 5.05 Million USD | -655.485% |
| Femasys Inc. | 667.11 Thousand USD | -5618.928% |
| GlucoTrack, Inc. | - USD | -Infinity% |
| Harvard Bioscience, Inc. | 24.71 Million USD | -54.362% |
| Hologic, Inc. | 679.8 Million USD | 94.388% |
| ICU Medical, Inc. | 709.36 Million USD | 94.622% |
| Intuitive Surgical, Inc. | 1.22 Billion USD | 96.874% |
| KORU Medical Systems, Inc. | 3.48 Million USD | -995.912% |
| LeMaitre Vascular, Inc. | 52.33 Million USD | 27.098% |
| Innovative Eyewear, Inc. | 856.75 Thousand USD | -4353.061% |
| Innovative Eyewear, Inc. | 856.75 Thousand USD | -4353.061% |
| Masimo Corporation | 545 Million USD | 93.0% |
| Microbot Medical Inc. | - USD | -Infinity% |
| Meihua International Medical Technologies Co., Ltd. | 1.61 Million USD | -2259.103% |
| Merit Medical Systems, Inc. | 303.87 Million USD | 87.445% |
| Nephros, Inc. | 2.47 Million USD | -1444.615% |
| NEXGEL, Inc. | 1.31 Million USD | -2792.494% |
| NEXGEL, Inc. | 1.31 Million USD | -2792.494% |
| Singular Genomics Systems, Inc. | 13.57 Million USD | -181.108% |
| OraSure Technologies, Inc. | 47.61 Million USD | 19.872% |
| Pro-Dex, Inc. | 15.26 Million USD | -149.866% |
| Pulse Biosciences, Inc. | - USD | -Infinity% |
| Predictive Oncology Inc. | 494.37 Thousand USD | -7617.234% |
| Precision Optics Corporation, Inc. | 2.86 Million USD | -1230.219% |
| QuidelOrtho Corporation | 577.8 Million USD | 93.397% |
| Repligen Corporation | 202.32 Million USD | 81.143% |
| Sanara MedTech Inc. | 4.71 Million USD | -708.728% |
| STAAR Surgical Company | 35.13 Million USD | -8.602% |
| Sharps Technology, Inc. | 1.7 Million USD | -2132.24% |
| Utah Medical Products, Inc. | 9.58 Million USD | -298.163% |
| DENTSPLY SIRONA Inc. | 624 Million USD | 93.886% |
| Jin Medical International Ltd. | 5.05 Million USD | -655.016% |